KEY POINTS
- This systematic review and meta-analysis searched PubMed, Embase and Cochrane through May 2026 and included six prospective randomized controlled studies evaluating prophylactic dexamethasone or another glucocorticoid during palliative radiotherapy for painful bone metastases.
- The primary endpoint was radiation-induced pain flare, a transient worsening of pain shortly after treatment. Using a random-effects model, prophylactic corticosteroids significantly lowered the risk compared with placebo or no prophylaxis: RR 0.63 (95% CI 0.46–0.86)—approximately a 37% relative reduction.
- Individual trial results were not uniform. Event counts ranged from 39/148 versus 53/150 in the largest dexamethasone comparison to 4/60 versus 12/60 in the methylprednisolone study, and sensitivity analyses did not identify one study responsible for the observed heterogeneity.
- Treatment schedules varied substantially. Included regimens ranged from single-fraction 8-Gy radiotherapy to multifraction schedules, with steroid approaches including oral dexamethasone around treatment, several-day prophylaxis and longer intravenous schedules. One trial used intravenous methylprednisolone rather than dexamethasone.
- The variation matters clinically because this meta-analysis supports the principle of steroid prophylaxis, but does not establish whether one dose before RT, four days of dexamethasone or a longer course provides the optimal balance between benefit and adverse effects.
- Safety evidence was much weaker than efficacy evidence. Adverse events were incompletely reported; the review noted three hyperglycemic events in one large dexamethasone study, while another trial reported no steroid-related adverse events and no severe treatment-related complications emerged across the included literature.
- The evidence base remains relatively small, with differing definitions, radiation schedules, steroid regimens and patient populations. The authors therefore stop short of defining a universal prophylactic protocol and call for further standardized randomized trials.
CLINICAL TAKEAWAY
For patients receiving palliative radiotherapy for painful bone metastases, the pooled randomized evidence supports prophylactic dexamethasone as a reasonable strategy to reduce pain flare. What remains uncertain is the optimal dose and duration, and the sparse safety reporting matters particularly in patients at risk of hyperglycemia, infection or other corticosteroid complications.